SCHEMBL19652146

SCHEMBL19652146

CC(C)(C)C(=O)NC1CCN(c2ccccc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 1/20 0.59
SKP1 P63208 1/20 0.59
SKP2 Q13309 1/20 0.59
EPHX2 P34913 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.52
ME3 Q16798 1/20 0.52
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
DRD2 P14416 3/20 0.51
DRD3 P35462 2/20 0.51
NPY5R Q15761 1/20 0.51
GPR119 Q8TDV5 1/20 0.50
DRD4 P21917 1/20 0.50
SSTR4 P31391 1/20 0.49
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.47
NOTUM Q6P988 1/20 0.46
USP30 Q70CQ3 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19658840 0.83 DRD2 (0.65) CKS1BSKP1SKP2EPHX2SMN1; SMN2
SCHEMBL17748966 0.82 EPHX2 (0.61) EPHX2SMN1; SMN2ME3ALDH1A1DRD2
SCHEMBL17830852 0.81 CKS1B (0.61) CKS1BSKP1SKP2EPHX2SMN1; SMN2
SCHEMBL17846438 0.80 EPHX2 (0.58) EPHX2SMN1; SMN2ME3ALDH1A1DRD2
SCHEMBL19652126 0.79 CKS1B (0.63) CKS1BSKP1SKP2SMN1; SMN2ALDH1A1
SCHEMBL3209065 0.79 ME3 (0.63) EPHX2SMN1; SMN2ME3DRD2DRD3
SCHEMBL25680457 0.79 EPHX2 (0.54) EPHX2SMN1; SMN2ME3ALDH1A1NPSR1
SCHEMBL13003260 0.78 SIGMAR1 (0.68) DRD2DRD3DRD4
SCHEMBL19652097 0.78 MEN1 (0.55) CKS1BSKP1SKP2ALDH1A1LMNA
SCHEMBL3637427 0.77 MTNR1A (0.61) EPHX2SMN1; SMN2ME3DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10258603-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-04-16 US disclosed
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 US disclosed
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10258603-B2 Therapeutic compounds and uses thereof BRD4, BRDT, BRD3 CKS1B 239/4885SKP1 2240/4885SKP2 2256/4885
US-20170340604-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF BRD4, BRDT, BRD3 CKS1B 239/4885SKP1 2240/4885SKP2 2256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.